Page 852 - Clinical Immunology_ Principles and Practice ( PDFDrive )

824 Part SIX Systemic Immune Diseases

23. Seko Y, Minota S, Kawasaki A, et al. Perforin-secreting killer cell 35. Achkar AA, Lie JT, Hunder GG, et al. How does previous corticosteroid
infiltration and expression of a 65-kD heat-shock protein in aortic tissue treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann
of patients with Takayasu’s arteritis. J Clin Invest 1994;93(2):750–8. Intern Med 1994;120(12):987–92.
24. Wen Z, Shimojima Y, Shirai T, et al. NADPH oxidase deficiency underlies 36. Jia L, Couce M, Barnholtz-Sloan JS, et al. Is all inflammation within
dysfunction of aged CD8+ Tregs. J Clin Invest 2016;126(5):1953–67. temporal artery biopsies temporal arteritis? Hum Pathol 2016;57:17–21.
25. Zhang H, Watanabe R, Berry GJ, et al. Immunoinhibitory checkpoint 37. Steeds RP, Mohiaddin R. Takayasu arteritis: role of cardiovascular
deficiency in medium and large vessel vasculitis. Proc Natl Acad Sci USA magnetic imaging. Int J Cardiol 2006;109(1):1–6.
2017;114(6):E970–9. 38. Hartlage GR, Palios J, Barron BJ, et al. Multimodality imaging of aortitis.
26. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. JACC Cardiovasc Imaging. 2014;7(6):605–19.
Ann Intern Med 2003;139(6):505–15. 39. Goronzy JJ, Weyand CM. Understanding immunosenescence to improve
27. Brack A, Rittner HL, Younge BR, et al. Glucocorticoid-mediated responses to vaccines. Nat Immunol 2013;14(5):428–36.
repression of cytokine gene transcription in human arteritis-SCID 40. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell
chimeras. J Clin Invest 1997;99(12):2842–50. arteritis using induction therapy with high-dose glucocorticoids: a
28. Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active double-blind, placebo-controlled, randomized prospective clinical trial.
polymyalgia rheumatica. Ann Intern Med 1997;127(1):27–31. Arthritis Rheum 2006;54(10):3310–18.
29. Caspary L. Inflammatory diseases of the aorta. Vasa. 2016;45(1):17–29. 41. Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical
30. Kobayashi Y, Numano F. 3. Takayasu arteritis. Intern Med management of giant cell arteritis and Takayasu arteritis. Curr Opin
2002;41(1):44–6. Rheumatol 2016;28(3):211–17.
31. Hunder GG, Bloch DA, Michel BA, et al. The American College of 42. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance
Rheumatology 1990 criteria for the classification of giant cell arteritis. of glucocorticosteroid-induced remission of giant cell arteritis: a
Arthritis Rheum 1990;33(8):1122–8. randomized trial. Ann Intern Med 2007;146(9):621–30.
32. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional 43. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for
classification criteria for polymyalgia rheumatica: a European League treatment of giant cell arteritis: an individual patient data meta-analysis.
Against Rheumatism/American College of Rheumatology collaborative Arthritis Rheum 2007;56(8):2789–97.
initiative. Arthritis Rheum 2012;64(4):943–54. 44. Liang P, Hoffman GS. Advances in the medical and surgical treatment of
33. Arend WP, Michel BA, Bloch DA, et al. The American College of Takayasu arteritis. Curr Opin Rheumatol 2005;17(1):16–24.
Rheumatology 1990 criteria for the classification of Takayasu arteritis. 45. Mason JC. Takayasu arteritis: surgical interventions. Curr Opin
Arthritis Rheum 1990;33(8):1129–34. Rheumatol 2015;27(1):45–52.
34. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern
Med 1994;120(11):919–29.